Clinical Study on Shenshi Jiangzhuo Formula in Treating Non-Alcoholic Fatty Liver Disease with Phlegm Blended with Stasis Syndrome
10.13359/j.cnki.gzxbtcm.2025.10.013
- VernacularTitle:渗湿降浊方治疗痰瘀互结型非酒精性脂肪性肝病的临床研究
- Author:
Ziqi LIN
1
;
Zheng XU
;
Zhiyang HUANG
;
Zheng WEN
;
Fanwei WU
Author Information
1. 广州中医药大学第七临床医学院,广东 深圳 518000;深圳市宝安区中医院,广东 深圳 518000
- Keywords:
Shenshi Jiangzhuo Formula;
non-alcoholic fatty liver disease(NAFLD);
phlegm blended with stasis syndrome;
controlled attenuation parameter;
liver function;
blood lipids;
TCM syndrome
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(10):2451-2457
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of Shenshi Jiangzhuo Formula(composed of Poria,Atractylodis Rhizoma,Magnoliae Officinalis Cortex,Pinelliae Rhizoma Praeparatum,Aurantii Fructus Immaturus,Arecae Semen,Talcum,Tetrapanacis Medulla,Notoginseng Radix et Rhizoma,Paeoniae Radix Rubra,Rubiae Radix et Rhizoma,Broussonetiae Fructus,etc.)in treating non-alcoholic fatty liver disease(NAFLD)with phlegm blended with stasis syndrome.Methods A total of 76 NAFLD patients with phlegm blended with stasis syndrome from the Seventh School of Clinical Medicine,Guangzhou University of Chinese Medicine(Shenzhen Bao'an Traditional Chinese Medicine Hospital)were enrolled between February 2024 and December 2024.The patients were randomly assigned(via random number table)to either the trial group(n=38,treated with Silibinin Meglumine Tablets plus Shenshi Jiangzhuo Formula)or the control group(n=38,treated with Silibinin Meglumine Tablets alone)for 8 weeks.The changes in liver controlled attenuation parameter(CAP),liver function markers[alanine aminotransferase(ALT),aspartate aminotransferase(AST),gamma-glutamyl transferase(GGT)],lipid profiles[triglycerides(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C)],and traditional Chinese medicine(TCM)syndrome scores were observed before and after treatment.Clinical efficacy and safety were evaluated.Results(1)One case dropped out from each group during the study and 37 cases in each group were included for final statistics.(2)After 8 weeks of treatment,the overall response rate in the trial group was 94.59％(35/37),compared with 62.16％(23/37)in the control group.Intergroup comparison revealed that the trial group demonstrated significantly superior overall therapeutic efficacy(by rank-sum test)and overall response rate(by chi-square test)compared with the control group(P＜0.01).(3)Both groups showed improved CAP values after treatment,and the trial group demonstrated significantly greater improvement compared to the control group(P＜0.01).(4)Post-treatment improvements in alanine aminotransferase(ALT),aspartate aminotransferase(AST),and gamma-glutamyl transferase(GGT)were improved in both groups(P＜0.01),with the trial group showing significantly superior improvements(P＜0.05 or P＜0.01).(5)Triglycerides(TG),total cholesterol(TC),and low-density lipoprotein cholesterol(LDL-C)were improved in both groups after treatment,and the trial group exhibited significantly better outcomes(P＜0.01).(6)Both groups presented reduced TCM syndrome scores after treatment,and the trial group showed greater reduction(P＜0.01).(7)No significant adverse recations were observed in both groups,showing high safety.Conclusion Integrative therapy with Shenshi Jiangzhuo Formula exerts certain effects in improving CAP values,liver function,lipid metabolism,and TCM symptoms in NAFLD patients with phlegm blended with stasis syndrome,demonstrating robust clinical value.
